Dexrazoxane
- Generic Name
- Dexrazoxane
- Brand Names
- Savene, Totect, Zinecard
- Drug Type
- Small Molecule
- Chemical Formula
- C11H16N4O4
- CAS Number
- 24584-09-6
- Unique Ingredient Identifier
- 048L81261F
- Background
An antimitotic agent with immunosuppressive properties. Dexrazoxane, the (+)-enantiomorph of razoxane, provides cardioprotection against anthracycline toxicity. It appears to inhibit formation of a toxic iron-anthracycline complex. [PubChem]
...
- Indication
For reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin hydrochloride dose of 300 mg/m^2 and would benefit from continued doxorubicin therapy. Also approved for the treatment of extravasation from intravenous anthracyclines.
- Associated Conditions
- Doxorubicin Induced Cardiomyopathy, Drug Extravasation
- Associated Therapies
- -
Doxorubicin With Cisplatin, High-Dose Methotrexate, and Additional Risk-Adapted Outpatient Chemotherapy
- First Posted Date
- 2008-05-07
- Last Posted Date
- 2014-09-10
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 7
- Registration Number
- NCT00673179
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Efficacy of TopotectTM (Dexrazoxane) for Accidental Extravasation of Anthracyclines
- Conditions
- First Posted Date
- 2007-10-24
- Last Posted Date
- 2015-10-21
- Lead Sponsor
- Valerio Therapeutics
- Target Recruit Count
- 23
- Registration Number
- NCT00548561
- Locations
- 🇩🇰
Aalborg Hospital South, Aalborg, Denmark
🇩🇰Rigshospitalet, Copenhagen, Denmark
🇩🇰Herlev County Hospital, Herlev, Denmark
A Clinical Trial on Topotect® (Dexrazoxane) in the Treatment of Accidental Extravasation of Anthracyclines
- Conditions
- First Posted Date
- 2007-10-24
- Last Posted Date
- 2015-10-21
- Lead Sponsor
- Valerio Therapeutics
- Target Recruit Count
- 57
- Registration Number
- NCT00548704
- Locations
- 🇵🇱
Centre of Oncology - Krakow Division, Krakow, Poland
🇵🇱Dolnoslaski Centrum Onkologii oddzial Chemoterapii, Wroclaw, Poland
🇩🇰Aarhus County Hospital, Aarhus, Denmark
Palonosetron in Sarcoma Patients Receiving Chemotherapy With Adriamycin and Ifosfamide (AI)
- First Posted Date
- 2006-12-13
- Last Posted Date
- 2013-03-22
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 51
- Registration Number
- NCT00410488
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Treatment of Childhood Acute Lymphoblastic Leukemia
- Conditions
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2007-12-28
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 491
- Registration Number
- NCT00165087
- Locations
- 🇺🇸
Ochsner Clinic, New Orleans, Louisiana, United States
🇨🇦McMaster University, Hamilton, Ontario, Canada
🇺🇸Maine Medical Center, Lewiston, Maine, United States
Vincristine, Doxorubicin, Cyclophosphamide and Dexrazoxane (VACdxr) in High Risk Ewing's Sarcoma Patients
- Conditions
- Interventions
- First Posted Date
- 2002-05-30
- Last Posted Date
- 2020-01-29
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 46
- Registration Number
- NCT00038142
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.